INT16432

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 1984
Last Reported 2007
Negated 0
Speculated 1
Reported most in Abstract
Documents 12
Total Number 13
Disease Relevance 1.15
Pain Relevance 5.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Lnpep) plasma membrane (Lnpep) intracellular (Lnpep)
cytoplasm (Lnpep)
Anatomy Link Frequency
neurons 4
SCN 4
neural lobe 2
SON 2
Lnpep (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 16 99.70 Very High Very High Very High
opiate 2 99.68 Very High Very High Very High
Enkephalin 4 99.52 Very High Very High Very High
antagonist 8 99.40 Very High Very High Very High
noradrenaline 6 99.22 Very High Very High Very High
Pain 1 98.78 Very High Very High Very High
tetrodotoxin 16 98.66 Very High Very High Very High
fluoxetine 21 98.28 Very High Very High Very High
Clonidine 2 98.08 Very High Very High Very High
sSRI 6 97.44 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hyponatremia 9 99.90 Very High Very High Very High
Stress 2 99.20 Very High Very High Very High
Pressure And Volume Under Development 1 80.48 Quite High
Decapitation 3 62.24 Quite High
Increased Venous Pressure Under Development 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The pathogenesis of this effect is not known, but enhanced release of vasopressin (VP) and its renal actions may be a possible mechanism.
Positive_regulation (enhanced) of Localization (release) of VP
1) Confidence 0.32 Published 1998 Journal Endocrine Section Abstract Doc Link 9666340 Disease Relevance 0.26 Pain Relevance 0.41
The peak rate of VP release was reached shortly after the onset of burst discharge. when intraburst firing rate was highest, and both effects were dose-dependent when tested to different concentrations of phenylephrine.
Positive_regulation (reached) of Localization (release) of VP
2) Confidence 0.19 Published 1986 Journal Brain Res. Section Abstract Doc Link 3004655 Disease Relevance 0 Pain Relevance 0.45
We determine if chronic fluoxetine administration in association with liberal fluid intake will induce hyponatremia via enhanced release of VP.
Positive_regulation (enhanced) of Localization (release) of VP associated with hyponatremia and fluoxetine
3) Confidence 0.19 Published 1998 Journal Endocrine Section Abstract Doc Link 9666340 Disease Relevance 0.34 Pain Relevance 0.42
Excess secretion of VP in combination with large fluid intake is known to induce hyponatremia.
Positive_regulation (Excess) of Localization (secretion) of VP associated with hyponatremia
4) Confidence 0.19 Published 1998 Journal Endocrine Section Abstract Doc Link 9666340 Disease Relevance 0.27 Pain Relevance 0.42
NA and the alpha 1-agonist phenylephrine stimulated VP release and elicited bursts in tuberal supraoptic neurons, whereas isoprenaline (a beta-agonist) and clonidine (an alpha 2-agonist) did not.
Positive_regulation (stimulated) of Localization (release) of VP in neurons associated with agonist, noradrenaline and clonidine
5) Confidence 0.17 Published 1986 Journal Brain Res. Section Abstract Doc Link 3004655 Disease Relevance 0 Pain Relevance 0.47
Supraoptic nucleus (SON) neurons receive a dense innervation from noradrenergic fibers, the activity of which stimulates vasopressin (VP) and oxytocin (OT) release, notably during homeostatic regulation of blood pressure and volume.
Positive_regulation (stimulates) of Localization (release) of VP in SON
6) Confidence 0.16 Published 2007 Journal Neuroscience Section Abstract Doc Link 17693027 Disease Relevance 0 Pain Relevance 0.11
In SCN explants experiencing this TTX-induced arrest of circadian VP output, subsequent exposure to KCl induced acute increases in VP release, suggesting that VP neurons retain the capacity to actively release peptide in spite of this effect of TTX.
Positive_regulation (induced) of Localization (release) of VP in SCN associated with tetrodotoxin
7) Confidence 0.08 Published 1991 Journal Brain Res. Bull. Section Abstract Doc Link 1933388 Disease Relevance 0 Pain Relevance 0.60
In SCN explants experiencing this TTX-induced arrest of circadian VP output, subsequent exposure to KCl induced acute increases in VP release, suggesting that VP neurons retain the capacity to actively release peptide in spite of this effect of TTX.
Positive_regulation (increases) of Localization (release) of VP in SCN associated with tetrodotoxin
8) Confidence 0.08 Published 1991 Journal Brain Res. Bull. Section Abstract Doc Link 1933388 Disease Relevance 0 Pain Relevance 0.60
VP secretion from magnocellular (MNC) neurons of the paraventricular nucleus (PVN) of the hypothalamus at the posterior pituitary and/or median eminence contributes to increasing adrenocorticotropin hormone (ACTH) output and ultimately glucocorticoid release, which then contributes to the stress response.
Positive_regulation (contributes) of Localization (secretion) of VP in neurons associated with stress
9) Confidence 0.06 Published 2005 Journal Regul. Pept. Section Abstract Doc Link 15927699 Disease Relevance 0.19 Pain Relevance 0.09
Therefore, NO selectively inhibits OT release in response to a painful stimulus (needle prick) and moderate osmotic stimulation to promote a preferential release of VP.
Positive_regulation (promote) of Localization (release) of VP associated with pain
10) Confidence 0.06 Published 1997 Journal Am. J. Physiol. Section Abstract Doc Link 9321882 Disease Relevance 0.08 Pain Relevance 0.13
Neither drug affected the basal release of OT or the basal or electrically stimulated release of VP.
Positive_regulation (stimulated) of Localization (release) of VP
11) Confidence 0.04 Published 1991 Journal Neuroendocrinology Section Abstract Doc Link 1831247 Disease Relevance 0 Pain Relevance 0.42
Electrical stimulation produced marked increases in release of both neural lobe peptides in a Ca(2+)-dependent manner, and the electrically evoked release of OT, but not VP, was enhanced by the opiate antagonist naltrexone (10 microM).
Positive_regulation (enhanced) of Localization (release) of VP in neural lobe associated with antagonist and opiate
12) Confidence 0.04 Published 1991 Journal Neuroendocrinology Section Abstract Doc Link 1831247 Disease Relevance 0 Pain Relevance 0.65
The effect of leucine5 -enkephalin on angiotensin II (AII)-stimulated release of oxytocin and vasopressin (VP) was investigated in the conscious male rat.
Spec (investigated) Positive_regulation (-stimulated) of Localization (release) of VP associated with enkephalin
13) Confidence 0.03 Published 1984 Journal Brain Res. Section Abstract Doc Link 6722545 Disease Relevance 0 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox